192 related articles for article (PubMed ID: 34966652)
1. Clinicopathological and Prognostic Value of Programmed Cell Death 1 Expression in Hepatitis B Virus-related Hepatocellular Carcinoma: A Meta-analysis.
Zhou ZY; Liu SR; Xu LB; Liu C; Zhang R
J Clin Transl Hepatol; 2021 Dec; 9(6):889-897. PubMed ID: 34966652
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
3. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y
Front Oncol; 2019; 9():897. PubMed ID: 31620360
[No Abstract] [Full Text] [Related]
4. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
Li XS; Li JW; Li H; Jiang T
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
[TBL] [Abstract][Full Text] [Related]
5. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.
Yang H; Zhou X; Sun L; Mao Y
Front Oncol; 2019; 9():47. PubMed ID: 30891423
[No Abstract] [Full Text] [Related]
6. Clinicopathological and Prognostic Roles of the Expression Levels of the Programmed Cell Death-1 Gene in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Yang J; Zhang W; Zhang Z; Song F; Ding M; Zhao X; Wang W; Yang Y
Genet Test Mol Biomarkers; 2020 Oct; 24(10):641-648. PubMed ID: 32990474
[No Abstract] [Full Text] [Related]
7. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142
[TBL] [Abstract][Full Text] [Related]
8. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
9. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M
Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Wang Q; Liu F; Liu L
Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis.
Zhang Q; Zhou K; Liang W; Xiong W
J Int Med Res; 2020 Oct; 48(10):300060520962675. PubMed ID: 33100077
[TBL] [Abstract][Full Text] [Related]
12. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
He J; Chen XF; Xu MG; Zhao J
Arch Oral Biol; 2020 Jun; 114():104717. PubMed ID: 32344357
[TBL] [Abstract][Full Text] [Related]
13. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X
Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677
[No Abstract] [Full Text] [Related]
14. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Lu L; Li Y; Luo R; Xu J; Feng J; Wang M
Front Oncol; 2020; 10():632. PubMed ID: 32426281
[No Abstract] [Full Text] [Related]
15. The EpCAM overexpression is associated with clinicopathological significance and prognosis in hepatocellular carcinoma patients: A systematic review and meta-analysis.
Zhou L; Zhu Y
Int J Surg; 2018 Aug; 56():274-280. PubMed ID: 29936198
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z
Front Pharmacol; 2019; 10():962. PubMed ID: 31616289
[No Abstract] [Full Text] [Related]
17. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
Wang F; Yu T; Ma C; Yuan H; Zhang H; Zhang Z
Front Oncol; 2020; 10():749. PubMed ID: 32582532
[No Abstract] [Full Text] [Related]
19. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Zhang C; Yang Q
Front Oncol; 2020; 10():572203. PubMed ID: 33634012
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]